Compare Ascendis Pharma A/S (ASND) vs Enovix Corporation (ENVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Enovix Corporation — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while Enovix Corporation trades at $4.87 (market cap $1.01B). The key difference: Ascendis Pharma A/S is far larger — about 16.6× Enovix Corporation's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ASND | ENVX | |
|---|---|---|
Market Cap | $16.78B | $1.01B |
Sector | Health | Technology |
52-Week High | $277.18 | $13.19 |
52-Week Low | $189.74 | $3.68 |
Enterprise Value | $17.15B | $1.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.
ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.
ENVX trades at $4.70, up 10.33% today, with a bullish technical signal despite negative profitability. Recent earnings beats and a $12.38 consensus price target suggest upside potential. The company is ramping production of advanced silicon-anode batteries, with key developments including a new COO appointment and upcoming Q2 2026 results on August 12, 2026.
Outlook remains speculative with high revenue growth potential but persistent losses; risks include cash burn and competitive pressures. Analyst sentiment is positive (75% buy ratings), but investors should weigh the long-term growth story against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
